{"references": ["Correll, C.U., Rummel-Kluge, C., Corves, C., Kane, J.M., & Leucht, S. (2009). Antipsychotic combinations versus monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Bulletin, 35(2), 443-457.", "Freudenreich, O., Goff, D.C. (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica, 106(5), 323-30.", "Ito, C., Kubota, Y., & Sato, M. (1999). A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry and Clinical Neurosciences, 53(1), S35-S40.", "Katzung (2010). Antidepressants: Katzung (2010) review. The Feria Journal of Medicine. Retrieved from http://theferiajournalofmedicine.blogspot.com/2010/10/antidepressants-katzung-2010-review.html", "Keks, N.A., Altson, K., Hope, J., et al (1999). Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Australian and New Zealand Journal of Psychiatry, 33(1), 896-901.", "Langan, J., & Shajahan, P. (2010). Antipsychotic polypharmacy: Review of mechanisms, mortality and management. Psychiatric Bulletin, 34(1). 58-62. doi: 10.1192/pb.bp.108.024257", "McCombs, J.S., Nichol, M.B., Johnstone, B.M., Stimmel, G.L., Shi, J., & Smith, R. (2000). Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatric Services. 51(4), 525-527.", "Sim, K., Su, A., Fujii, S., Yang, S.Y., Chong, M.Y., et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58(1), 178\u2013183. doi: 10.1111/j.1365-2125.2004.02102.x", "Tapp, A., Wood, A.E., Secrest, L., Erdmann, J., Cubberley, L., & Kilzieh, N. (2003). Combination antipsychotic therapy in clinical practice. Psychiatric Services, 54(1), 55-59. doi: 10.1176/appi.ps.54.1.55-59", "Xiang, Y.T., Wang, C.Y., Si, T.M., Lee, E.H., He, Y.L., Ungvari, G.S., et al. (2011). Clozapine use in schizophrenia: Findings of the research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. Australian and New Zealand Journal of Psychiatry, 45(1), 968\u2013975."]}

The study determines the antipsychotic polypharmacy in selected Asian countries particularly Japan, Singapore, Korea, China, Taiwan, and Hongkong. It is a descriptive correlational study that utilizes the clustering data mining technique. Gathered data from the internal and analyzed using appropriate statistical management. Findings reveal that Japan and Singapore have the highest prevalence of antipsychotic polypharmacy. In terms of care settings, antipsychotic polypharmacy is prevalently high in both general hospitals and psychiatric facilities. Being male of increasing age and the duration of illness are directly directly proportional to the prevalence of antipsychotic polypharmacy.